Clinical trials: Drug Interaction Study
B-cell Malignancies
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
- Trial name
- NCT04551963
- Testing
- Zanubrutinib, Fluconazole, Diltiazem
- Where
- 7 sites in Australia
- Volunteers
- 26 people
- Sponsor
- BeiGene
Healthy Volunteers
Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
This Phase 1, open-label, single-sequence, non-randomized, multiple-dose, crossover pharmacokinetic study is a single site study in the United States and will be conducted to assess the effect of a CYP1A2 inducer (omeprazole 40…
- Trial name
- NCT03866434
- Testing
- SPD422, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteer
Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults
The primary objective of Part 1 of the study is to evaluate the safety and tolerability of S-648414 after administration of a single oral dose of S-648414 in healthy adult study participants.
- Trial name
- NCT04147715
- Testing
- S-648414, Midazolam, Dolutegravir
- Where
- 2 sites in United States, Japan
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Shionogi
Solid Cancers
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment…
- Trial name
- NCT01209143
- Testing
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Genentech, Inc.
Advanced Melanoma
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine
- Trial name
- NCT00796991
- Testing
- Ipilimumab, Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Hypertension
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
Pulmonary Arterial Hypertension (PAH) is a severe progressive disease with a high mortality. Although several drugs are available for the treatment of PAH none offer a cure, therefore there is still a high medical need for new…
- Trial name
- PATENT PLUS (NCT01179334)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil
- Where
- 25 sites in United States, Austria and 7 more
- Volunteers
- 18 people
- Sponsor
- Bayer
Drug Drug Interaction
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
Primary objective: To evaluate the plasma and urine PK of Givinostat following multiple oral doses of Givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of Givinostat.
- Trial name
- NCT05860114
- Testing
- Givinostat
- Where
- Portugal
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Japanese Healthy Adult Males
Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam
The purpose of this study is to evaluate the effect of repeated-dose administration of itraconazole on the pharmacokinetics of TAK-272, as well as the effect of repeated-dose administration of TAK-272 on the pharmacokinetics of…
- Trial name
- NCT02370615
- Testing
- TAK-272, Digoxin, Itraconazole
- Where
- Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Takeda
Hepatic Impairment, Moderate Impaired Hepatic Function
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3).
- Trial name
- NCT04473664
- Testing
- Quizartinib
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Healthy Subjects, Drug-drug Interaction
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
- Trial name
- NCT04459598
- Testing
- Efavirenz, Quizartinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Healthy
Drug-Drug Interaction Study: ASP2151 and Bupropion
CYP2B6 is involved in the metabolism of many drugs. So, it is important to assess in vivo the effect of ASP2151 on that enzyme to determine any possible drug interactions.
- Trial name
- NCT02369172
- Testing
- Bupropion, ASP2151
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Healthy
A Food-Drug Interaction Study of Serum Urate After Oral Inosine
The purpose of this study is to assess the effects of food on the amount of urate in the body after a single oral dose of inosine.
- Trial name
- NCT02614469
- Testing
- Inosine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Michael Alan Schwarzschild
Healthy
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants.
- Trial name
- NCT05788328
- Testing
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cancer
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts.
- Trial name
- NCT01072175
- Testing
- GSK2118436, GSK1120212
- Where
- 15 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers
- Trial name
- NCT02283814
- Testing
- BIA 2-093, Topamax
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat.
- Trial name
- NCT02540668
- Testing
- Lanabecestat, Warfarin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type2 Diabetes Mellitus
Bexagliflozin Drug/Drug Interaction Study With Digoxin
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with the heart failure medication digoxin.
- Trial name
- NCT03197324
- Testing
- Bexagliflozin, Digoxin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Theracos
Healthy Female Participants
A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants
The purpose of the study is to investigate the effect of steady-state padsevonil on the pharmacokinetic of a single dose oral contraceptive.
- Trial name
- NCT04131517
- Testing
- Padsevonil, Microgynon 30®
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Hypertension and Chronic Heart Failure
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
- Trial name
- NCT02151994
- Testing
- BIA 5-1058
- Where
- Netherlands
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Multidrug-resistant Tuberculosis, Extensively Drug-resistant Tuberculosis
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Future patients might benefit from a combination of linezolid (LIN) and clarithromycin (CLA) in the treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) due to possible synergistic activity as…
- Trial name
- NCT01521364
- Testing
- Addition of different doses of clarithromycin.
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- University Medical Center Groningen